| Patent application number | Description | Published |
|---|
| 20090149438 | Pyrimidines as PLK inhibitors - The present invention encompasses compounds of general formula (1), | 06-11-2009 |
| 20090163465 | Pyrimidines as PLK inhibitors - The present invention encompasses compounds of general formula (1), | 06-25-2009 |
| 20090163467 | New compounds - The present invention encompasses compounds of general formula (1) | 06-25-2009 |
| 20090203683 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM - A compound of formula (I) | 08-13-2009 |
| 20090318480 | METHOD FOR TREATING CANCER HARBORING EGFR MUTATIONS - The present invention relates to a method of treatment of patients suffering from cancer and harbouring mutations of EGFR in the tumour, for instance an activating mutation of the EGFR or a mutation responsible for resistance or the emergence of acquired resistance to treatment with reversible EGFR and/or HER2 inhibitors or irreversible inhibitors such as CI-1033, EKB-569, HKI-272 or HKI-357, comprising administering an effective amount of the irreversible EGFR inhibitor BIBW2992 (1) 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, to a person in need of such treatment, optionally in combination with the administration of a further chemotherapeutic agent, in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, and to the use of a BIBW 2992 (1) for preparing a pharmaceutical composition for the treatment of patients suffering from cancer and harbouring mutations of EGFR in the tumour. | 12-24-2009 |
| 20100010023 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - A compound of general formula I | 01-14-2010 |
| 20100069414 | BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESSES FOR PREPARING THEM - The present invention relates to bicyclic heterocycles of general formula | 03-18-2010 |
| 20100144706 | Compounds - The present invention encompasses compounds of general formula (1) wherein R | 06-10-2010 |
| 20100222331 | NEW COMPOUNDS - The present invention encompasses compounds of general Formula (1) wherein R | 09-02-2010 |
| 20110039863 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS - The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. | 02-17-2011 |
| 20110046168 | METHODS OF TREATING DISEASES USING QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - A compound of general formula I | 02-24-2011 |
| 20110086842 | Pyrimidines as PLK inhibitors - The present invention encompasses compounds of general formula (1), | 04-14-2011 |
| 20110136826 | COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS - The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said diseases, comprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations. | 06-09-2011 |
